Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Q1 2023 Earnings Call Transcript

Operator: Thank you. And I show our next question comes from the line of Brian Skorney from Baird. Please go ahead.

Luke Herrmann: Hey, this is Luke again. Just one more for us. On SPRINT criteria, is there any reason to expect meaningfully different antiviral or clinical impact in patients treated after five days of symptoms as opposed to someone who goes and then gets treated on day one? And is that a cross-section you’ll look at when you cut the data?

Jay Luly: We’ll have a little bit of a cut in terms of timing on that. I think it’s less than three days versus greater than three days up to five days. So, we’ll see what we see. In general, almost always, the earlier you treat is more optimal. But COVID has been a little bit more forgiving than some other viruses. So we’ll just wait and see. We’ll collect the data and look at it, and again, that will help inform how we progress.

Operator: Thank you. And I do show we have another question from Roy Buchanan from JMP Securities. Please go ahead.

Roy Buchanan: Hey, thanks for taking the follow-up. Jay you mentioned some combo trials that you’re tracking, data readouts that are coming up. Can you tell us what those are?

Jay Luly: Maybe I’ll turn that over to Tara. You’re talking about an HBV again?

Roy Buchanan: Yes. Thanks.

Tara Kieffer: Sure. Roy, hi it’s Tara. So we’ll certainly be looking at all the combination studies that are going on out there today. So that would include Roche’s larger trial that is looking at combinations that they have with their siRNA and immune modulators. Also is running a number of trials now with their siRNA as well as looking at therapeutic vaccine. They’re also doing a trial with their monoclonal antibody combination and also one with interferon. And then they’re additionally looking at one with a TLR-8 from €“ that’s in combination with Gilead. Our Arbutus a couples ongoing. They have an siRNA in combination with interferon. So we’ll be looking at that trial as well. GSK obviously is moving forward with their ASO alone and in combination with Interferon. So we’ll be curious to see readouts for all of these trials.

Operator: Thank you. That concludes our Q&A session. I show no further questions at this time. I’d like to call back over to Jennifer Viera for closing remarks.

Jennifer Viera: Thank you, operator, and thanks to everyone for joining us today. If you have additional questions, feel free to contact us by e-mail or call us at the office. Thanks, and have a good night. Bye-bye.

Operator: Thank you. This concludes today’s conference call. Thank you for participating. You may now disconnect.